Use of triiodothyronine to treat critically ill COVID-19 patients: a new clinical trial
- PMID: 32384906
- PMCID: PMC7209969
- DOI: 10.1186/s13054-020-02934-2
Use of triiodothyronine to treat critically ill COVID-19 patients: a new clinical trial
Conflict of interest statement
The following pending patents are relevant to the work in this manuscript:
• PCT/EP2019/087056. L-triiodothyronine (T3) for use in limiting microvascular obstruction
• Greek Patent Office, number of case: 22-0002577373. Composition comprising L-triiodothyronine (T3) for use in the treatment of critically ill patients with coronavirus infection.
IT, managing director of Uni-Pharma, is the sponsor and owner of these patents. CP and IM are the inventors and hold royalties in relation to these patents.
Figures
Comment on
-
Translating thyroid hormone effects into clinical practice: the relevance of thyroid hormone receptor α1 in cardiac repair.Heart Fail Rev. 2015 May;20(3):273-82. doi: 10.1007/s10741-014-9465-4. Heart Fail Rev. 2015. PMID: 25501869 Review.
References
-
- Marchant D, Dou Y, Luo H, Garmaroudi FS, McDonough JE, Si X, et al. Bosentan enhances viral load via endothelin-1 receptor type-A-mediated p38 mitogen-activated protein kinase activation while improving cardiac function during coxsackievirus-induced myocarditis. Circ Res. 2009;104:813–821. doi: 10.1161/CIRCRESAHA.108.191171. - DOI - PubMed
-
- Sato R, Ariyoshi N, Hasegawa D, Crossey E, Hamahata N, Ishihara T, et al. Effects of inotropes on the mortality in patients with septic shock. J Intensive Care Med 2019:885066619892218. doi: 10.1177/0885066619892218. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
